| 1 |
34162179 |
10.3324/haematol.2021.278743 |
2022 |
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. |
EZH2 |
| 2 |
34382383 |
10.3324/haematol.2020.263251 |
2022 |
Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma. |
EZH2 |
| 3 |
34601504 |
10.1038/s41379-021-00938-z |
2022 |
Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation. |
EZH2 |
| 4 |
34655667 |
10.1016/j.canlet.2021.10.010 |
2022 |
EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition. |
EZH2 |
| 5 |
34788984 |
10.3324/haematol.2021.279177 |
2022 |
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials. |
EZH2 |
| 6 |
34793663 |
10.4143/crt.2021.1121 |
2022 |
Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma. |
EZH2 |
| 7 |
34837284 |
10.1111/cas.15224 |
2022 |
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma. |
EZH2 |
| 8 |
34904909 |
10.1080/14656566.2021.2014815 |
2022 |
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma. |
EZH2 |
| 9 |
34957565 |
10.1002/path.5861 |
2022 |
Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma. |
EZH2 |
| 10 |
35022084 |
10.1186/s13046-021-02234-9 |
2022 |
The follicular lymphoma epigenome regulates its microenvironment. |
EZH2 |
| 11 |
35031597 |
10.1038/s41420-022-00819-7 |
2022 |
ALKBH5-mediated N<sup>6</sup>-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation. |
EZH2 |
| 12 |
35034955 |
10.1038/s41375-021-01494-w |
2022 |
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. |
EZH2 |
| 13 |
35045798 |
10.1080/10428194.2021.2024821 |
2022 |
High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. |
EZH2 |
| 14 |
35082399 |
10.1038/s41417-021-00415-4 |
2022 |
CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma. |
EZH2 |
| 15 |
35086959 |
10.1158/1535-7163.MCT-21-0216 |
2022 |
Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype. |
EZH2 |
| 16 |
35151584 |
10.1016/j.clml.2021.12.014 |
2022 |
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. |
EZH2 |
| 17 |
35157216 |
10.1007/s12325-022-02054-z |
2022 |
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib. |
EZH2 |
| 18 |
35173526 |
10.7150/ijbs.64752 |
2022 |
SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC. |
EZH2 |
| 19 |
35180337 |
10.46883.2022.25920946 |
2022 |
Follicular Lymphoma: a Focus on Current and Emerging Therapies |
EZH2 |
| 20 |
35181615 |
|
2022 |
Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications. |
EZH2 |
| 21 |
35236331 |
10.1186/s12885-022-09237-5 |
2022 |
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. |
EZH2 |
| 22 |
35247900 |
10.1158/2643-3230.BCD-21-0098 |
2022 |
Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. |
EZH2 |
| 23 |
35250278 |
10.2147/OTT.S267011 |
2022 |
Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat. |
EZH2 |
| 24 |
35253299 |
10.1002/gcc.23036 |
2022 |
CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia. |
EZH2 |
| 25 |
35357654 |
10.1007/s13402-022-00663-y |
2022 |
BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer. |
EZH2 |
| 26 |
35369397 |
10.6004/jadpro.2022.13.2.7 |
2022 |
Tazemetostat: EZH2 Inhibitor. |
EZH2 |
| 27 |
35379077 |
10.1080/10428194.2022.2057488 |
2022 |
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. |
EZH2 |
| 28 |
35380993 |
10.1172/JCI145343 |
2022 |
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. |
EZH2 |
| 29 |
35454811 |
10.3390/cancers14081904 |
2022 |
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients. |
EZH2 |
| 30 |
35491222 |
10.11406/rinketsu.63.313 |
2022 |
[Epigenetic modification as a therapeutic approach for B-cell lymphoma]. |
EZH2 |
| 31 |
35522148 |
10.3324/haematol.2021.280005 |
2022 |
Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas. |
EZH2 |
| 32 |
35561310 |
10.1182/bloodadvances.2021006069 |
2022 |
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. |
EZH2 |
| 33 |
35562412 |
10.1038/s41379-022-01085-9 |
2022 |
Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. |
EZH2 |
| 34 |
35574216 |
10.18632/oncotarget.28229 |
2022 |
Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes. |
EZH2 |
| 35 |
35650206 |
10.1038/s41467-022-30651-7 |
2022 |
Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. |
EZH2 |
| 36 |
35661922 |
10.1007/s00428-022-03347-y |
2022 |
H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas. |
EZH2 |
| 37 |
35734596 |
10.3389/fonc.2022.846573 |
2022 |
The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China. |
EZH2 |
| 38 |
35753676 |
10.1016/j.bbagrm.2022.194840 |
2022 |
Chemical biology and pharmacology of histone lysine methylation inhibitors. |
EZH2 |
| 39 |
35772421 |
10.1016/S2352-3026(22)00169-7 |
2022 |
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma. |
EZH2 |
| 40 |
35772429 |
10.1016/S2352-3026(22)00134-X |
2022 |
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. |
EZH2 |
| 41 |
35795062 |
10.3389/fonc.2022.870487 |
2022 |
Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis. |
EZH2 |
| 42 |
35851487 |
10.1016/j.blre.2022.100988 |
2022 |
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. |
EZH2 |
| 43 |
35908982 |
10.1016/j.blre.2022.100992 |
2022 |
Follicular lymphoma: The long and winding road leading to your cure? |
EZH2 |
| 44 |
35941836 |
10.1080/15384101.2022.2109898 |
2022 |
ELK1-Induced upregulation of long non-coding TNK2-AS1 promotes the progression of acute myeloid leukemia by EZH2-mediated epigenetic silencing of CELF2. |
EZH2 |
| 45 |
35959380 |
10.2147/BLCTT.S282247 |
2022 |
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma? |
EZH2 |
| 46 |
35960849 |
10.1182/blood.2022016428 |
2022 |
Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma. |
EZH2 |
| 47 |
35973200 |
10.1182/bloodadvances.2022008403 |
2022 |
Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation. |
EZH2 |
| 48 |
36029326 |
10.1007/s00277-022-04914-8 |
2022 |
Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis. |
EZH2 |
| 49 |
36055572 |
10.1016/j.clim.2022.109105 |
2022 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. |
EZH2 |
| 50 |
32799209 |
10.1159/000509159 |
2021 |
The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma. |
EZH2 |
| 51 |
32855278 |
10.3324/haematol.2020.254854 |
2021 |
Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype. |
EZH2 |
| 52 |
33094664 |
10.1080/15476286.2020.1838783 |
2021 |
LncRNAs in adaptive immunity: role in physiological and pathological conditions. |
EZH2 |
| 53 |
33226554 |
10.1007/s12094-020-02504-6 |
2021 |
Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma. |
EZH2 |
| 54 |
33263441 |
10.1080/17474086.2021.1856652 |
2021 |
Development of molecular intervention strategies for B-cell lymphoma. |
EZH2 |
| 55 |
33270606 |
10.1172/JCI135711 |
2021 |
Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. |
EZH2 |
| 56 |
33271120 |
10.1016/j.immuni.2020.11.002 |
2021 |
Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. |
EZH2 |
| 57 |
33389794 |
10.1002/jcla.23693 |
2021 |
USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma. |
EZH2 |
| 58 |
33413063 |
10.2174/1568009620666210106122750 |
2021 |
Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). |
EZH2 |
| 59 |
33414134 |
10.1158/1078-0432.CCR-20-2378 |
2021 |
Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. |
EZH2 |
| 60 |
33431788 |
10.1038/s41392-020-00437-8 |
2021 |
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. |
EZH2 |
| 61 |
33436855 |
10.1038/s41598-020-80613-6 |
2021 |
Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia. |
EZH2 |
| 62 |
33492746 |
10.1111/cas.14822 |
2021 |
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. |
EZH2 |
| 63 |
33502806 |
10.1002/biof.1704 |
2021 |
BCL-6 promotes the methylation of miR-34a by recruiting EZH2 and upregulating CTRP9 to protect ischemic myocardial injury. |
EZH2 |
| 64 |
33513156 |
10.1371/journal.pone.0237554 |
2021 |
Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. |
EZH2 |
| 65 |
33529029 |
10.1021/acs.jmedchem.0c02112 |
2021 |
Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug. |
EZH2 |
| 66 |
33560380 |
10.1182/bloodadvances.2020002469 |
2021 |
Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. |
EZH2 |
| 67 |
33562694 |
10.3390/cancers13040641 |
2021 |
Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. |
EZH2 |
| 68 |
33616890 |
10.1007/s40265-020-01446-1 |
2021 |
Novel Therapy Approaches to Follicular Lymphoma. |
EZH2 |
| 69 |
33709777 |
10.2217/fon-2020-1244 |
2021 |
EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. |
EZH2 |
| 70 |
33711241 |
10.1080/14656566.2021.1902988 |
2021 |
Novel synthetic drugs for the treatment of non-Hodgkin lymphoma. |
EZH2 |
| 71 |
33747936 |
10.3389/fonc.2021.622648 |
2021 |
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. |
EZH2 |
| 72 |
33754292 |
10.1007/s11899-021-00614-8 |
2021 |
Targeted Therapies for Follicular Lymphoma. |
EZH2 |
| 73 |
33770460 |
10.1200/EDBK_320117 |
2021 |
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. |
EZH2 |
| 74 |
33792119 |
10.1111/cas.14905 |
2021 |
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. |
EZH2 |
| 75 |
33794893 |
10.1186/s12935-021-01897-w |
2021 |
Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. |
EZH2 |
| 76 |
33797691 |
10.1007/s11899-021-00617-5 |
2021 |
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma. |
EZH2 |
| 77 |
33821477 |
10.1002/ijc.33584 |
2021 |
A rare variant in EZH2 is associated with prostate cancer risk. |
EZH2 |
| 78 |
33829512 |
10.1111/his.14378 |
2021 |
Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma. |
EZH2 |
| 79 |
33899787 |
10.1097/PAS.0000000000001691 |
2021 |
The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma. |
EZH2 |
| 80 |
33904892 |
10.1182/bloodadvances.2020002773 |
2021 |
Treating lymphoma is now a bit EZ-er. |
EZH2 |
| 81 |
33935039 |
10.5045/br.2021.2021049 |
2021 |
Genomics of diffuse large B cell lymphoma. |
EZH2 |
| 82 |
33937922 |
10.1007/s11912-021-01076-0 |
2021 |
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs. |
EZH2 |
| 83 |
33959502 |
10.3389/fonc.2021.638897 |
2021 |
c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. |
EZH2 |
| 84 |
33997750 |
10.1016/j.jhepr.2021.100276 |
2021 |
Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. |
EZH2 |
| 85 |
34017197 |
10.2147/CMAR.S267258 |
2021 |
Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. |
EZH2 |
| 86 |
34044429 |
10.24875/RIC.21000070 |
2021 |
A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma. |
EZH2 |
| 87 |
34065087 |
10.3390/ijms22095013 |
2021 |
The Impact of Epigenetic Modifications in Myeloid Malignancies. |
EZH2 |
| 88 |
34069564 |
10.3390/ijms22105352 |
2021 |
The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential. |
EZH2 |
| 89 |
34094676 |
|
2021 |
HMGA1 induces EZH2 overexpression in human B-cell lymphomas. |
EZH2 |
| 90 |
34104370 |
10.1177/20406207211015882 |
2021 |
The role of tazemetostat in relapsed/refractory follicular lymphoma. |
EZH2 |
| 91 |
34105464 |
10.19746/j.cnki.issn.1009-2137.2021.03.012 |
2021 |
[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma]. |
EZH2 |
| 92 |
34159682 |
10.1111/cas.15040 |
2021 |
Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. |
EZH2 |
| 93 |
34168051 |
10.1158/1078-0432.CCR-20-4027 |
2021 |
Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma. |
EZH2 |
| 94 |
34193230 |
10.1186/s13045-021-01113-2 |
2021 |
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. |
EZH2 |
| 95 |
34196564 |
10.1021/acs.jmedchem.1c00460 |
2021 |
Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. |
EZH2 |
| 96 |
34202528 |
10.3390/cancers13133155 |
2021 |
Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types. |
EZH2 |
| 97 |
34204385 |
10.3390/cancers13123032 |
2021 |
Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing. |
EZH2 |
| 98 |
34321240 |
10.1158/0008-5472.CAN-21-1027 |
2021 |
Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL. |
EZH2 |
| 99 |
34351144 |
10.1021/acs.jmedchem.1c00226 |
2021 |
Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders. |
EZH2 |
| 100 |
34376807 |
10.1038/s41379-021-00885-9 |
2021 |
EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. |
EZH2 |
Datasets
Models
